NCT05481476

Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer

A Single-center, Single-arm, Phase II Clinical Study of Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 32 (estimated)
• Sponsor: Sun Yat-sen University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a single-center, single-arm, open-label, phase 2 clinical study, to explore the efficacy and safety of surufatinib combined with sintilimab and AG in first-line therapy of patients with locally advanced or metastatic pancreatic cancer.

Conditions

• Pancreatic Neoplasms

Interventions

Type	Name	Description
DRUG	Surufatinib	250mg, qd, po, 21 days for a cycle
DRUG	Sintilimab	200mg, ivgtt, d1, 21 days for a cycle, up to 2 years
DRUG	AG	nab-paclitaxel (125mg/ m2, ivgtt, d1, 8), Gemcitabine (1000mg/ m2, intravenous infusion over 30min, d1, 8), 21 days for a cycle, up to 6 cycles

Timeline

• Start date: 2022-12-12
• Primary completion: 2025-12-31
• Completion: 2026-12-31
• First posted: 2022-08-01
• Last updated: 2025-09-04

Locations

1 site across 1 country: China